Metagenomi, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGX research report →
Companywww.metagenomi.co
Metagenomi, Inc. , a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
- CEO
- Jian Irish
- IPO
- 2006
- Employees
- 202
- HQ
- Emeryville, US
Price Chart
Valuation
- Market Cap
- $48.56M
- P/E
- -0.56
- P/S
- 2.17
- P/B
- 0.35
- EV/EBITDA
- -0.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -12.54%
- Op Margin
- -415.48%
- Net Margin
- -384.61%
- ROE
- -51.23%
- ROIC
- -51.29%
Growth & Income
- Revenue
- $25.21M · -51.79%
- Net Income
- $-87,868,000 · -12.57%
- EPS
- $-2.36 · -12.92%
- Op Income
- $-96,013,000
- FCF YoY
- 20.25%
Performance & Tape
- 52W High
- $3.95
- 52W Low
- $1.24
- 50D MA
- $1.42
- 200D MA
- $1.81
- Beta
- 0.64
- Avg Volume
- 209.46K
Get TickerSpark's AI analysis on MGX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Irish Jian | other | 46,000 |
| Apr 1, 26 | Irish Jian | other | 276,000 |
| Apr 1, 26 | Wein Matthew | other | 11,000 |
| Apr 1, 26 | Wein Matthew | other | 68,000 |
| Apr 1, 26 | Wapnick Pamela | other | 24,000 |
| Apr 1, 26 | Wapnick Pamela | other | 144,000 |
| Mar 5, 26 | Wapnick Pamela | sell | 1,581 |
| Mar 5, 26 | Wein Matthew | sell | 482 |
| Dec 5, 25 | Irish Jian | other | 228,462 |
| Mar 5, 26 | Irish Jian | sell | 1,607 |
Our MGX Coverage
We haven't published any research on MGX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MGX Report →